Novartis 28 abr 2026 Novartis CEO calls for 'complete rethink' of Europe's drug pricing policies - Fierce Pharma
Novartis 28 abr 2026 Novartis’ sales dip as generics pressure intensifies, radioequivalents loom - BioSpace
Novartis 28 abr 2026 Novartis CEO warns reality of Trump's drug pricing policy will set in over 'the next 18 months' - CNBC
Novartis 28 abr 2026 Novartis CEO ‘continuing to evaluate’ in vivo CAR-Ts, but no deals in the works - Fierce Biotech
Novartis 27 abr 2026 Biopharma bites: 'Green shoots' for UK's biotech sector, Ligand buys XOMA and more from AstraZeneca, Novartis - FirstWord Pharma
FierceBiotech 22 abr 2026 Novartis narrows focus for anticoagulant after failure to best Eliquis in phase 3 trial
Novartis 20 abr 2026 Novartis Restructures Clinical Ops to Scale Trial Innovation Beyond Pilots - The Clinical Trial Vanguard
FierceBiotech 15 abr 2026 Novartis CEO Vas Narasimhan joins Anthropic’s board as biopharma’s ties to AI deepen
FierceBiotech 23 mar 2026 Novartis joins Lilly, AZ in China expansion with $480M commitment to boost manufacturing, R&D
FierceBiotech 20 mar 2026 Novartis pays Synnovation $2B upfront for breast cancer program as rivals circle
Endpoints News 20 mar 2026 Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
Endpoints News 26 feb 2026 Novartis to build another radioligand factory; Germany steps up probe into Gerresheimer